Drug Excretion in Breast Milk: Pharmacokinetics & Neonatal Dose Estimation

The Science of Drug Transfer into Breast Milk

Understanding how medications transfer from maternal circulation into breast milk is fundamental to lactation pharmacology. This knowledge enables clinicians to make evidence-based prescribing decisions and empowers mothers to understand the safety assessment process. Despite the common perception that any drug taken by a mother will harm her breastfed infant, the pharmacokinetics of drug excretion in breast milk demonstrate that most medications result in subtherapeutic, clinically insignificant infant exposure.

Breast milk is produced by lactocytes (mammary alveolar epithelial cells) that form a single-cell layer between maternal blood capillaries and the alveolar lumen. Drugs must cross this cellular barrier to enter breast milk. The transfer process is governed by well-established pharmacokinetic principles that are consistent across drug classes and can be quantitatively assessed using the milk-to-plasma (M/P) ratio and Relative Infant Dose (RID).

This article provides a detailed pharmacological foundation for understanding drug excretion in breast milk, designed for clinicians, pharmacists, and educated mothers seeking authoritative information. It references Hale's Medications & Mothers' Milk, LactMed, and established pharmacokinetic literature.

Mechanisms of Drug Transfer Across the Mammary Epithelium

Passive Diffusion: The Primary Pathway

The vast majority of drugs enter breast milk through passive diffusion, driven by the concentration gradient between maternal plasma and alveolar milk. No active transport mechanisms have been conclusively demonstrated for most pharmaceutical agents, making this a predictable, physicochemistry-dependent process.

The rate and extent of passive diffusion are determined by five key drug properties:

1. Molecular Weight

• Drugs with molecular weight below 200 daltons diffuse freely across the mammary epithelium.
• Drugs between 200-500 daltons transfer moderately.
• Drugs above 800 daltons transfer poorly or not at all.
• Drugs above 1000 daltons are essentially excluded from breast milk.

Drug	Molecular Weight (Da)	Transfer to Milk
Ethanol	46	Free transfer; M/P approximately 1.0
Paracetamol	151	Moderate transfer; M/P 0.76-1.42
Ibuprofen	206	Low transfer (high protein binding compensates)
Vancomycin	1,449	Minimal transfer
Insulin	5,808	No significant transfer
Heparin	3,000-30,000	No transfer; also destroyed in infant GI tract

2. Protein Binding

Only unbound (free) drug molecules can cross biological membranes. Therefore, drugs with high protein binding in maternal plasma have less free drug available for transfer into milk:

• Greater than 90% protein binding: Very low milk transfer. Examples: ibuprofen (99%), diclofenac (99.7%), warfarin (99%).
• 50-90% protein binding: Moderate milk transfer possible.
• Less than 50% protein binding: Higher milk transfer likely if other factors are favourable.

This explains why ibuprofen, despite having a moderate molecular weight, has an exceptionally low RID of 0.1-0.7%, as its 99% protein binding leaves virtually no free drug for mammary transfer.

3. Lipophilicity

Breast milk contains 3-5% fat, and the lipid content varies during a feed (higher in hindmilk) and across the day. Lipophilic (fat-soluble) drugs dissolve readily in the milk fat globule membrane and can achieve higher milk concentrations. Key points include:

• Highly lipophilic drugs (e.g., diazepam, metronidazole) may have M/P ratios above 1.
• The partition coefficient (LogP) predicts lipophilicity: higher LogP correlates with greater milk transfer.
• However, high lipophilicity does not automatically mean high infant exposure if the drug is also highly protein-bound.

4. Ionization State and Ion Trapping

Breast milk has a pH of 6.8-7.2, slightly more acidic than maternal plasma (pH 7.4). This pH difference creates a phenomenon called ion trapping:

• Weak bases (pKa above 7.4) are more ionized in the relatively acidic milk, becoming trapped and unable to diffuse back into plasma.
• This leads to accumulation in milk and M/P ratios above 1 for weak bases.
• Weak acids (pKa below 7.4) tend to remain in plasma, with M/P ratios below 1.
• Most drugs are weak bases, which is why many common medications have M/P ratios modestly above 1 without being clinically dangerous.

5. Maternal Half-Life

A drug's elimination half-life determines how long it persists in maternal plasma and, consequently, how long it continues to diffuse into milk:

• Short half-life drugs (under 6 hours) are cleared quickly, reducing cumulative infant exposure.
• Long half-life drugs or those with active metabolites (e.g., fluoxetine, diazepam) maintain sustained milk levels, increasing the infant dose over time.
• Timing feeds to trough drug levels (just before the next dose) can reduce infant exposure for short half-life drugs.

Calculating the Milk-to-Plasma (M/P) Ratio

The M/P ratio is the fundamental measure of drug partitioning into breast milk:

M/P Ratio = Concentration of drug in milk (Cmilk) / Concentration of drug in plasma (Cplasma)

Interpreting M/P Ratios

M/P Ratio	Interpretation	Example Drugs
Below 0.5	Drug favours plasma; low milk transfer	Paroxetine (0.06-1.3), Cefazolin (0.02)
0.5-1.0	Moderate transfer; equilibrium	Azithromycin (0.5), Paracetamol (0.76-1.42)
1.0-2.0	Drug concentrates in milk; assess RID	Citalopram (1.2-3.5), Metronidazole (0.4-1.8)
Above 2.0	Significant milk concentration; evaluate absolute dose	Sertraline (1.5-3.3), Iodine

Critical point: M/P ratio alone does not determine safety. A drug with an M/P ratio of 3 but very low maternal plasma levels will still deliver a tiny absolute dose to the infant. This is why Relative Infant Dose is the more clinically useful metric.

Relative Infant Dose (RID): The Clinical Gold Standard

Step-by-Step RID Calculation

RID quantifies the infant's weight-adjusted drug exposure as a percentage of the mother's weight-adjusted dose:

1. Step 1: Estimate infant dose via milk
   Infant Dose (mg/kg/day) = Average drug concentration in milk (Cavg, mg/L) x Estimated daily milk intake (150 mL/kg/day for a fully breastfed infant) / 1000
2. Step 2: Calculate maternal weight-adjusted dose
   Maternal Dose (mg/kg/day) = Total maternal daily dose (mg) / Maternal weight (kg)
3. Step 3: Calculate RID
   RID (%) = (Infant Dose mg/kg/day / Maternal Dose mg/kg/day) x 100

Worked Example: Sertraline

Consider a 70 kg mother taking sertraline 100 mg/day, breastfeeding a 4 kg term infant:

• Average sertraline concentration in milk: 45 mcg/L (0.045 mg/L)
• Infant dose via milk: 0.045 x 0.15 (L/kg/day) = 0.00675 mg/kg/day
• Maternal weight-adjusted dose: 100/70 = 1.43 mg/kg/day
• RID = (0.00675 / 1.43) x 100 = 0.47%

This confirms sertraline's published RID range of 0.4-2.2%, well below the 10% safety threshold.

RID Safety Thresholds

RID Range	Clinical Interpretation	Recommendation
Below 2%	Very low exposure; excellent safety	Generally safe for all infants including preterm
2-5%	Low exposure; good safety margin	Safe for term infants; monitor preterm
5-10%	Moderate exposure; acceptable safety	Generally safe for term; use caution in preterm
10-25%	Significant exposure; potential concern	Use only if benefit outweighs risk; monitor infant
Above 25%	High exposure; probable clinical effect	Generally incompatible with breastfeeding

Oral Bioavailability in the Infant: The Overlooked Safety Factor

Even if a drug is present in breast milk, the infant must be able to absorb it from their gastrointestinal tract for it to have any pharmacological effect. This is where oral bioavailability becomes a crucial safety consideration:

• Aminoglycosides (gentamicin, amikacin): Essentially zero oral bioavailability. Even if present in milk, the infant's gut cannot absorb them. These are safe during breastfeeding despite parenteral toxicity.
• Heparin and low-molecular-weight heparins: Destroyed in the infant's GI tract; zero oral bioavailability. Completely safe during breastfeeding.
• Insulin: A large protein (5808 Da) that does not transfer into milk in significant amounts and is digested if ingested orally. Safe during breastfeeding.
• Vancomycin: Poor oral absorption (less than 5%) and high molecular weight limit both transfer and infant uptake.

Neonatal Drug Metabolism: Why Premature Infants Are More Vulnerable

The neonatal capacity to metabolize and eliminate drugs is dramatically different from adults, and this capacity varies with gestational and postnatal age:

Parameter	Term Neonate	Preterm Neonate (below 34 weeks)	Adult
CYP3A4 activity	30-50% of adult	10-20% of adult	100%
CYP2D6 activity	20-40% of adult	Less than 10% of adult	100%
Renal clearance (GFR)	2-4 mL/min	0.6-0.8 mL/min	120 mL/min
Protein binding	Reduced (lower albumin)	Significantly reduced	Normal
Body fat percentage	12-15%	1-3%	18-25%

These immature systems mean that even small drug doses delivered through breast milk may accumulate in preterm infants. For this reason, some lactation pharmacologists recommend using a lower RID safety threshold of 5% for preterm neonates, particularly those in NICU settings.

HEAMAC neonatal care services recognize the importance of careful drug monitoring in NICU patients. For newborns receiving phototherapy for jaundice, awareness of concurrent maternal drug exposure through breast milk adds an important layer to comprehensive neonatal management.

Special Milk Composition Factors

Colostrum vs Mature Milk

Drug transfer may differ between colostrum (produced in the first 3-5 days) and mature milk due to compositional differences:

• Colostrum has wider intercellular gaps in mammary epithelium, potentially allowing greater drug transfer.
• However, colostral volume is very small (2-20 mL per feed), so the absolute drug amount delivered is low.
• Mature milk has a higher fat content, which may increase partitioning of lipophilic drugs.

Foremilk vs Hindmilk

Hindmilk has 2-3 times the fat content of foremilk. For lipophilic drugs, this means higher drug concentrations in hindmilk. However, the clinical significance of this variation is minimal for most medications at standard doses.

Practical Applications for Indian Clinicians

Indian clinicians can apply these pharmacokinetic principles to evaluate any drug not specifically listed in Hale's reference or LactMed:

1. Check molecular weight: above 800 Da is likely safe.
2. Assess protein binding: above 90% significantly limits milk transfer.
3. Evaluate oral bioavailability: poor oral bioavailability in the infant provides an additional safety margin.
4. Consider half-life: prefer shorter half-life drugs within the same class.
5. Calculate or reference RID: below 10% for term infants, below 5% for preterm.
6. Review infant age: neonates (especially preterm) have the least drug clearance capacity; older infants metabolize drugs more efficiently.

Key Principle: When choosing between two equally effective drugs for a breastfeeding mother, select the one with higher protein binding, shorter half-life, higher molecular weight, and lower oral bioavailability. This pharmacokinetic-based selection process minimizes infant exposure while allowing effective maternal treatment.

Conclusion: Pharmacokinetics Empowers Evidence-Based Decisions

Drug excretion in breast milk follows predictable pharmacokinetic principles. By understanding molecular weight, protein binding, lipophilicity, ionization, and half-life, clinicians can assess the safety of virtually any medication during breastfeeding. The Relative Infant Dose provides the most clinically relevant quantitative metric, with the widely accepted threshold of below 10% for term infants and below 5% for preterm infants. Resources such as Hale's Medications & Mothers' Milk, LactMed, and the IAP drug formulary should be consulted for specific drug data. When pharmacokinetic principles are properly applied, the vast majority of maternal medications are compatible with safe, continued breastfeeding.